---
title: "Foreign and domestic institutional investors conduct over 900 research visits to A-share companies, focusing on two core sectors: high-end manufacturing and technological innovation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280380184.md"
description: "As of March 24, foreign institutional investors have conducted over 900 research visits to A-share companies, covering 271 listed companies. Renowned foreign institutions such as BlackRock and Goldman Sachs participated in these visits. BeiGene received research visits from 81 foreign institutions, ranking first; HUAMING and Orbbec also garnered attention. Foreign capital is primarily focusing on high-end manufacturing and technological innovation sectors"
datetime: "2026-03-24T23:04:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280380184.md)
  - [en](https://longbridge.com/en/news/280380184.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280380184.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280380184.md) | [繁體中文](https://longbridge.com/zh-HK/news/280380184.md)


# Foreign and domestic institutional investors conduct over 900 research visits to A-share companies, focusing on two core sectors: high-end manufacturing and technological innovation

Wind information data shows that as of March 24, foreign institutional investors have conducted over 900 research visits, covering 271 A-share listed companies. Among them, well-known foreign institutions such as BlackRock, Goldman Sachs, UBS Asset Management, Point72 Asset Management, Fidelity International, and Morgan Stanley have all appeared on the research list. In terms of individual stocks researched, BeiGene received visits from 81 foreign institutions, ranking first among all stocks; HUAMING, Orbbec, Instar, Inovance Technology, and Opto-Tech each received visits from over 50 foreign institutions. Looking at the sectors to which these stocks belong, the main focus of foreign institutional investors' attention on A-shares is concentrated on the two core sectors of high-end manufacturing and technological innovation. (Securities Daily)

### Related Stocks

- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [BeOne Medicines (688235.CN)](https://longbridge.com/en/quote/688235.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md)
- [HUAMING (002270.CN)](https://longbridge.com/en/quote/002270.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md)
- [Orbbec (688322.CN)](https://longbridge.com/en/quote/688322.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)
- [TransThera Sciences Widens Annual Loss Amid Continued R&D Spend](https://longbridge.com/en/news/281187419.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/en/news/281343251.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/en/news/280992698.md)